Antibacterial Activity of Gold Nanoparticles Conjugated by Aminoglycosides Against A. baumannii Isolates from Burn Patients.

Mehdi Rostami Rad, Hossein Kazemian, Fateme Yazdani, Mohammad Reza Zand Monfared, Hoseinali Rahdar, Ali Javadi, Mansoor Kodori
{"title":"Antibacterial Activity of Gold Nanoparticles Conjugated by Aminoglycosides Against <i>A. baumannii</i> Isolates from Burn Patients.","authors":"Mehdi Rostami Rad,&nbsp;Hossein Kazemian,&nbsp;Fateme Yazdani,&nbsp;Mohammad Reza Zand Monfared,&nbsp;Hoseinali Rahdar,&nbsp;Ali Javadi,&nbsp;Mansoor Kodori","doi":"10.2174/1574891X13666180828115543","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Today, resistance to multiple classes of antibiotics, and notably to the β-lactam and aminoglycosides in A. baumannii is becoming a great problem and it necessitates to make a new approach to combat with multidrug-resistant (MDR), extensive drug-resistance (XDR) or Pandrug-resistant (PDR) isolates. In this case, a new strategy and ways should be designed and introduced against such infections. Therefore the aim of the present study was the evaluation of antibacterial activity of nanoconjugate gentamicin and amikacin with gold against clinical isolates of A. baumannii that were collected from burn wound infection. There are some patents of gold nanoparticles that are conjugated with antibiotics (WO2017161296A1, US20090181101A1).</p><p><strong>Methods: </strong>Eighteen A. baumannii were collected from burn wound infections. For confirmation and detection of aminoglycoside-resistant genes, PCR was carried out. Gold nanoparticles and nanoconjugates were prepared according to the protocol. For the evaluation of the nanoconjugate, Dynamic light cattering, Transmission electron microscopy and FTIR Analysis were carried out. Then, the antibacterial activity of nanoconjugates was conducted by using micro broth dilution method.</p><p><strong>Result: </strong>Prevalence of aminoglycoside-resistant genes was aacC1, aphA6, aadA1, aadB genes 55.5%, 22.2%, 38.8% and 22.2% respectively. Synthesis of bare nanoconjugates resulted in nanoparticle in a size of 10 nm. Amikacin bound to Gnps showed excellent antibacterial activity (94.5%) and just one isolate showed intermediate resistance. Also, gentamicin bound to Gnps had a good antimicrobial effect (50%) in contrast to gentamicin alone.</p><p><strong>Conclusion: </strong>Our study showed that a combination of amikacin and gentamicin with Gnps has a significant antibacterial efficiency against clinical isolates of A. baumannii. Gnps can be used as extraordinary molecular carriers for targeting, and delivery of the antibiotic molecules to the specific infection.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X13666180828115543","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5

Abstract

Background and objective: Today, resistance to multiple classes of antibiotics, and notably to the β-lactam and aminoglycosides in A. baumannii is becoming a great problem and it necessitates to make a new approach to combat with multidrug-resistant (MDR), extensive drug-resistance (XDR) or Pandrug-resistant (PDR) isolates. In this case, a new strategy and ways should be designed and introduced against such infections. Therefore the aim of the present study was the evaluation of antibacterial activity of nanoconjugate gentamicin and amikacin with gold against clinical isolates of A. baumannii that were collected from burn wound infection. There are some patents of gold nanoparticles that are conjugated with antibiotics (WO2017161296A1, US20090181101A1).

Methods: Eighteen A. baumannii were collected from burn wound infections. For confirmation and detection of aminoglycoside-resistant genes, PCR was carried out. Gold nanoparticles and nanoconjugates were prepared according to the protocol. For the evaluation of the nanoconjugate, Dynamic light cattering, Transmission electron microscopy and FTIR Analysis were carried out. Then, the antibacterial activity of nanoconjugates was conducted by using micro broth dilution method.

Result: Prevalence of aminoglycoside-resistant genes was aacC1, aphA6, aadA1, aadB genes 55.5%, 22.2%, 38.8% and 22.2% respectively. Synthesis of bare nanoconjugates resulted in nanoparticle in a size of 10 nm. Amikacin bound to Gnps showed excellent antibacterial activity (94.5%) and just one isolate showed intermediate resistance. Also, gentamicin bound to Gnps had a good antimicrobial effect (50%) in contrast to gentamicin alone.

Conclusion: Our study showed that a combination of amikacin and gentamicin with Gnps has a significant antibacterial efficiency against clinical isolates of A. baumannii. Gnps can be used as extraordinary molecular carriers for targeting, and delivery of the antibiotic molecules to the specific infection.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氨基糖苷偶联金纳米颗粒对烧伤鲍曼不动杆菌的抗菌活性研究。
背景与目的:鲍曼不饱和杆菌对多种抗生素的耐药,特别是对β-内酰胺和氨基糖苷类抗生素的耐药已成为一个严重的问题,因此有必要制定新的方法来对抗多重耐药(MDR)、广泛耐药(XDR)或泛耐药(PDR)分离株。在这种情况下,应该设计和采用新的策略和方法来防止这种感染。因此,本研究的目的是评价纳米结合庆大霉素和含金阿米卡星对烧伤创面感染临床分离鲍曼不动杆菌的抗菌活性。与抗生素偶联的金纳米颗粒有一些专利(WO2017161296A1, US20090181101A1)。方法:采集烧伤创面感染鲍曼不动杆菌18只。为确认和检测氨基糖苷耐药基因,采用PCR方法。根据该方案制备了金纳米颗粒和纳米缀合物。为了对纳米共轭物进行评价,进行了动态光散射、透射电镜和红外光谱分析。然后,采用微肉汤稀释法对纳米缀合物进行抑菌活性测定。结果:氨基糖苷耐药基因为aacC1、aphA6、aadA1、aadB基因,分别占55.5%、22.2%、38.8%和22.2%。裸纳米缀合物的合成得到了10 nm大小的纳米颗粒。与Gnps结合的阿米卡星具有良好的抗菌活性(94.5%),仅有1株菌株表现出中等耐药性。与单独使用庆大霉素相比,与Gnps结合的庆大霉素具有良好的抗菌效果(50%)。结论:本研究表明,阿米卡星、庆大霉素联合Gnps对鲍曼不动杆菌临床分离株具有显著的抗菌效果。Gnps可以作为特殊的分子载体,用于靶向和递送抗生素分子到特定的感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Recent patents on anti-infective drug discovery
Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)
CiteScore
2.40
自引率
0.00%
发文量
1
期刊介绍: Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
期刊最新文献
Essential oils as alternative antimicrobials: current status The Staphylococcal Cassette Chromosome mec (SCCmec) Analysis and Biofilm Formation of Methicillin-Resistant Staphylococcus cohnii Isolated from Clinical Samples in Tehran, Iran. Meet Our Associate Editor Secondary metabolites of endophytic fungi from Newbouldia laevis and Cassia tora leaves: prospecting for new antimicrobial agents. Meet Our Editor-in-Chief
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1